EAGLE was a randomized phase-III study that compared the anti-PD-L1 mAb durvalumab plus the CTLA4 inhibitor tremelimumab to chemotherapy in R/M HNSCC. Here, CTLA4 is linked to head and neck squamous cell carcinoma.